Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712360 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
A Phase 4 study, sponsored by Merz North America.
- Completed
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
NCT01712360 is a Phase 4 study that has completed, run by Merz North America. The registered enrollment target is 56 participants.
The verdict
NCT01712360, a Phase 4 study, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch. Safety of the drug and how well the drug works will also be measured.
Interventions
- DRUG NAFT500 (pediatric)
- DRUG NAFT600 (pediatric)
- DRUG NAFT500 (adult)
- DRUG NAFT600 (adult)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01712360
The ClinicalTrials.gov registry entry for NCT01712360 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz North America, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which NAFT500 (pediatric) is the first listed.
NCT01712360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01712360 about?
NCT01712360 is a clinical study titled "Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis". This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch. Safety of the drug and how well the drug works will also be measured.
What is the current status of trial NCT01712360?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2012-10. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01712360?
The interventions under investigation include: NAFT500 (pediatric) (DRUG), NAFT600 (pediatric) (DRUG), NAFT500 (adult) (DRUG), NAFT600 (adult) (DRUG).
Who is sponsoring clinical trial NCT01712360?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.